Share General Information
Ivosidenib, sold under the brand name Tibsovo, is used in adults whose cancer is newly diagnosed and who are either 75 years and older or cannot be treated with other anticancer drugs. Ivosidenib blocks the protein made by the mutated IDH1 gene. Blocking this protein may help keep cancer cells from growing. Ivosidenib is a type of enzyme inhibitor and a type of targeted therapy for patients diagnosed with Glioma, Acute Myeloid Leukemia (AML), Cholangiocarcinoma, and Chondrosarcoma.
About the API
-
Japan DMF
-
Korea DMF
-
US DMF
Updates About Ivosidenib API
The information detailed herein, including that with regard to active pharmaceutical ingredients , their use in treatments and possible mechanism(s) of action, was all obtained from public sources.
For more information on our services and products – including product suitability, intended uses and current availability – please contact Teva api Customer Service. CAS Registry Number is a Registered Trademark of the American Chemical Society. This webpage and any reference to the above product is to be read within the meaning and terms of the Legal Notes.
